Macroprolactin causes falsely elevated prolactin levels and separating it clarifies persistent hyperprolactinemia.

Hyperprolactinemia is a common clinical finding, but its interpretation is complicated by the presence of different molecular forms of the hormone. Macroprolactin, a large complex of prolactin and immunoglobulin G (IgG), frequently causes artifactual elevations in serum prolactin levels, a condition known as macroprolactinemia.

Clinical and effectiveness evidence

Research confirms that macroprolactinemia is a frequent cause of elevated prolactin, accounting for 10% to 46% of all hyperprolactinemia cases. Because standard immunoassays often cannot distinguish between bioactive monomeric prolactin and the inactive macroprolactin complex, patients may present with significantly elevated total prolactin levels despite being asymptomatic.

• Diagnostic screening: The Endocrine Society and other clinical bodies recommend screening for macroprolactin, particularly in patients with mild or asymptomatic hyperprolactinemia.
• Separation methods: Polyethylene glycol (PEG) precipitation is the standard clinical method for separating macroprolactin. A recovery of less than 40% to 60% of prolactin after PEG treatment typically indicates significant macroprolactinemia, whereas a recovery of >80% suggests true hyperprolactinemia (excess monomeric hormone).

Mechanistic explanations

The discrepancy between measured levels and clinical symptoms is rooted in the molecular structure and behavior of macroprolactin:

• Assay interference: Macroprolactin (~150 kDa) is much larger than monomeric prolactin (23 kDa). In standard "sandwich" immunoassays, the complex cross-reacts with both capture and detection antibodies, leading to high total readings.
• Reduced biological activity: The IgG antibody often binds to prolactin near its receptor-binding site, creating steric hindrance that prevents the hormone from activating its receptors in vivo.
• Reduced clearance: Due to its large molecular size, macroprolactin has a lower renal clearance rate than monomeric prolactin, causing it to accumulate in the bloodstream and further inflate measured levels.

Clinical implications

Identifying macroprolactin is essential for accurate diagnosis and patient management. By differentiating "true" hyperprolactinemia from "pseudohyperprolactinemia," clinicians can:

• Avoid unnecessary and expensive diagnostic imaging, such as pituitary MRIs.
• Prevent the initiation of inappropriate dopamine agonist therapy, sparing patients from potential side effects.
• Provide reassurance to patients who have biochemically high but clinically insignificant prolactin levels.

Bottom line

Macroprolactin causes falsely elevated prolactin readings due to its interference with standard lab assays, yet it remains biologically inactive. Separating macroprolactin—primarily through PEG precipitation—is a validated and essential step in interpreting persistent hyperprolactinemia to avoid misdiagnosis and unnecessary medical intervention.